Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndrome

References

• Haidar G, Mellors JW. Improving the outcomes of immunocompromised patients with coronavirus disease 2019. Clin Infect Dis. 2021;73(6):e1397–e1401.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly B, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
   PubMed Web of Science ®Google Scholar
• Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–1423.
   PubMed Web of Science ®Google Scholar
• Righi E, Gallo T, Azzini AM, et al. A review of vaccinations in adult patients with secondary immunodeficiency. Infect Dis Ther. 2021;10(2):637–661.
   PubMed Web of Science ®Google Scholar
• Haberman RH, Herati RS, Simon D, et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA Covid-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis. 2021;80(10):1339–1344.
   PubMed Web of Science ®Google Scholar
• Deepak P, Kim W, Paley MA, et al. Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. Ann Intern Med. 2021;174(11):1572–1585.
   PubMed Web of Science ®Google Scholar
• Rincon-Arevalo H, Choi M, Stefanski A-L, et al. Impaired humoral immunity to SARS-CoV-2 BNT 162b2 vaccine in kidney transplant recipients and dialysis patients. Sci Immunol. 2021;6(60):eabj1031.
   Web of Science ®Google Scholar
• Werbel WA, Boyarsky BJ, Ou MT, et al. Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Ann Intern Med. 2021;174(9):1330–1332.
   PubMed Web of Science ®Google Scholar
• Marion O, Kamar N, Del Bello A, et al. Safety and immunogenicity of anti-SARS-CoV-2 messenger RNA vaccines in recipients of solid organ transplants. Ann Intern Med. 2021;174(9):1336–1338.
   PubMed Web of Science ®Google Scholar
• Kamar N, Abravanel F, Marion O, et al. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385(7):661–662.
   PubMed Web of Science ®Google Scholar
• Tzarfati K, Gutwein O, Apel A, et al. BNT162b2 COVID‐19 vaccine is significantly less effective in patients with hematologic malignancies. American J Hematol. 2021;96(10):1195–1203.
   PubMed Web of Science ®Google Scholar
• Greenberger LM, Saltzman LA, Senefeld JW, et al. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021;39(8):1031–1033.
   PubMed Web of Science ®Google Scholar
• Mori A, Onozawa M, Tsukamoto S, et al. Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies. Br J Haematol. 2022;197(6):691–696.
   PubMed Web of Science ®Google Scholar
• Chan WY, Zhu C, Sanchez E, et al. Antibody responses to SARS-CoV-2 vaccination in patients with acute myeloid leukaemia and high risk MDS on active anti-cancer therapies. Br J Haematol. 2022;198(3):478–481.
   PubMed Web of Science ®Google Scholar
• Pichler D, Baumgartner M, Kimpel J, et al. Marked increase in avidity of SARS-CoV-2 antibodies 7-8 months after infection is not diminished in old age. J Infect Dis. 2021;224(5):764–770.
   PubMed Web of Science ®Google Scholar
• Yang HS, Costa V, Racine-Brzostek DE, et al. Association of age with SARS-CoV-2 antibody response. JAMA Netw Open. 2021;4(3):e214302.
   PubMed Web of Science ®Google Scholar
• Benner SE, Patel EU, Laeyendecker O, et al. SARS-CoV-2 antibody avidity responses in Covid-19 patients and convalescent plasma donors. J Infect Dis. 2020;222(12):1974–1984.
   PubMed Web of Science ®Google Scholar
• Fendler A, Shepherd STC, Au L, et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nat Cancer. 2021;2(12):1305–1320.
   PubMedGoogle Scholar
• Zeng C, Evans JP, Reisinger S, et al. Impaired neutralizing antibody response to Covid-19 mRNA vaccines in cancer patients. Cell Biosci. 2021;11(1):197.
   PubMed Web of Science ®Google Scholar
• Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, et al. The neutralizing antibody response post Covid-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J. 2021;11(8):138.
   PubMed Web of Science ®Google Scholar
• Gavriatopoulou M, Terpos E, Ntanasis-Stathopoulos I, et al. Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study. Blood Adv. 2021;5(21):4398–4405.
   PubMed Web of Science ®Google Scholar
• Chung DJ, Shah GL, Devlin SM, et al. Disease- and therapy-specific impact on humoral immune responses to Covid-19 vaccination in hematologic malignancies. Blood Cancer Discov. 2021;2(6):568–576.
   PubMedGoogle Scholar
• Racine-Brzostek SE, Karbaschi M, Gaebler C, et al. TOP-Plus is a versatile biosensor platform for monitoring SARS-CoV-2 antibody durability. Clin Chem. 2021;67(9):1249–1258.
   PubMed Web of Science ®Google Scholar
• Yang HS, Racine-Brzostek SE, Karbaschi M, et al. Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in Covid-19 patients. Biosens Bioelectron. 2021;178:113008.
   PubMed Web of Science ®Google Scholar
• Avivi I, Balaban R, Shragai T, et al. Humoral response rate and predictors of response to BNT 162b2 mRNA Covid19 vaccine in patients with multiple myeloma. Br J Haematol. 2021;195(2):186–193.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT 162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165–3173.
   PubMed Web of Science ®Google Scholar
• Chan PKS, Lim P-L, Liu EYM, et al. Antibody avidity maturation during severe acute respiratory syndrome-associated coronavirus infection. J Infect Dis. 2005;192(1):166–169.
   PubMed Web of Science ®Google Scholar
• Hedman K, Hietala J, Tiilikainen A, et al. Maturation of immunoglobulin G avidity after rubella vaccination studied by an enzyme linked immunosorbent assay (avidity-ELISA) and by haemolysis typing. J Med Virol. 1989;27(4):293–298.
   PubMed Web of Science ®Google Scholar
• Bauer G. The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2. Int J Infect Dis. 2021;106:61–64.
   PubMed Web of Science ®Google Scholar
• Bauer G, Struck F, Schreiner P, et al. The challenge of avidity determination in SARS-CoV-2 serology. J Med Virol. 2021;93(5):3092–3104.
   PubMed Web of Science ®Google Scholar
• Luo YR, Chakraborty I, Yun C, et al. Kinetics of SARS-CoV-2 antibody avidity maturation and association with disease severity. Clin Infect Dis. 2021;73(9):e3095–e3097.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211.
   PubMed Web of Science ®Google Scholar
• Malard F, Gaugler B, Gozlan J, et al. Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Cancer J. 2021;11(8):142.
   PubMed Web of Science ®Google Scholar
• Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. J Amer Med Assoc. 2021;325(21):2204–2206.
   PubMed Web of Science ®Google Scholar
• Steensels D, Pierlet N, Penders J, et al. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. J Amer Med Assoc. 2021;326(15):1533–1535.
   PubMed Web of Science ®Google Scholar
• Richards NE, Keshavarz B, Workman LJ, et al. Comparison of SARS-CoV-2 antibody response by age among recipients of the BNT162b2 vs the mRNA-1273 vaccine. JAMA Netw Open. 2021;4(9):e2124331.
   PubMed Web of Science ®Google Scholar
• Puranik A, Lenehan PJ, Silvert E, et al. Comparison of two highly-effective mRNA vaccines for Covid-19 during periods of alpha and delta variant prevalence. medRxiv [Preprint]. 2021 Aug 21:2021.08.06.21261707. doi: 10.1101/2021.08.06.21261707. PMID: 34401884; PMCID: PMC8366801.
   Google Scholar
• Grannis SJ, Rowley EA, Ong TC, et al. Interim estimates of Covid-19 vaccine effectiveness against Covid-19-associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B.1.617.2 (Delta) variant predominance- nine states, June-August 2021. MMWR Morb Mortal Wkly Rep. 2021;70(37):1291–1293.
   PubMed Web of Science ®Google Scholar
• Chodick G, Tene L, Rotem RS, et al. The effectiveness of the two-dose BNT162b2 vaccine: analysis of real-world data. Clin Infect Dis. 2022;74(3):472–478.
   PubMed Web of Science ®Google Scholar
• Tenforde MW, Patel MM, Ginde AA, et al. Effectiveness of SARS-CoV-2 mRNA vaccines for preventing Covid-19 hospitalizations in the United States. medRxiv [Preprint]. 2021 Jul 8:2021.07.08.21259776. doi: 10.1101/2021.07.08.21259776. Update in: Clin Infect Dis. 2021 Aug 06;: PMID: 34268515; PMCID: PMC8282104.
   Google Scholar
• Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized Covid-19 patients in Israel. Clin Microbiol Infect. 2021;27(11):1652–1657.
   PubMed Web of Science ®Google Scholar